|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mouabbi JA, Hassan A, Lim B, Hortobagyi
GN, Tripathy D and Layman RM: Invasive lobular carcinoma: An
understudied emergent subtype of breast cancer. Breast Cancer Res
Treat. 193:253–264. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas M, Kelly ED, Abraham J and Kruse M:
Invasive lobular breast cancer: A review of pathogenesis,
diagnosis, management, and future directions of early stage
disease. Semin Oncol. 46:121–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson N, Ironside A, Diana A and
Oikonomidou O: Lobular breast cancer: A review. Front Oncol.
10:5913992021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pramod N, Nigam A, Basree M, Mawalkar R,
Mehra S, Shinde N, Tozbikian G, Williams N, Majumder S and
Ramaswamy B: Comprehensive review of molecular mechanisms and
clinical features of invasive lobular cancer. Oncologist.
26:e943–e953. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Biglia N, Maggiorotto F, Liberale V,
Bounous VE, Sgro LG, Pecchio S, D'Alonzo M and Ponzone R:
Clinical-pathologic features, long term-outcome and surgical
treatment in a large series of patients with invasive lobular
carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg
Oncol. 39:455–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi YJ, Shin YD and Song YJ: Comparison
of ipsilateral breast tumor recurrence after breast-conserving
surgery between ductal carcinoma in situ and invasive breast
cancer. World J Surg Oncol. 14:1262016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giannakeas V, Sopik V and Narod SA:
Association of radiotherapy with survival in women treated for
ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw
Open. 1:e1811002018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boyages J and Baker L: Evolution of
radiotherapy techniques in breast conservation treatment. Gland
Surg. 7:5762018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai CJ, Huang HY, Chen FM, Yang YH, Chen
LC and Hsieh KP: Investigating the effectiveness of adjuvant
therapy for patients with hormone receptor-positive ductal
carcinoma in situ. PLoS One. 17:e02629342022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mills MN, Russo NW, Fahey M, Nanda RH,
Raiker S, Jastrzebski J, Stout LL, Wilson JP, Altoos TA, Allen KG,
et al: Increased risk for ipsilateral breast tumor recurrence in
invasive lobular carcinoma after accelerated partial breast
irradiation brachytherapy. Oncologist. 26:e1931–e1938. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanz-Garcia E, Zhao E, Bratman SV and Siu
LL: Monitoring and adapting cancer treatment using circulating
tumor DNA kinetics: Current research, opportunities, and
challenges. Sci Adv. 8:eabi86182022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zavarykina TM, Lomskova PK, Pronina IV,
Khokhlova SV, Stenina MB and Sukhikh GT: Circulating tumor DNA is a
variant of liquid biopsy with predictive and prognostic clinical
value in breast cancer patients. Int J Mol Sci. 24:170732023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arisi MF, Dotan E and Fernandez SV:
Circulating tumor DNA in precision oncology and its applications in
colorectal cancer. Int J Mol Sci. 23:44412022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reinert T, Henriksen TV, Christensen E,
Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin
AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing
in patients with stages I to III colorectal cancer. JAMA Oncol.
5:1124–1131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wolff AC, Hammond MEH, Hicks DG, Dowsett
M, McShane LM, Allison KH, Allred DC, Bertlett JMS, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
D'Orsi C, Bassett L and Feig S: Breast
imaging reporting and data system (BI-RADS). Breast Imaging Atlas.
4th edition. American College of Radiology; Reston, VA, USA: pp.
29–47. 2018
|
|
18
|
Amin MD, Gress DM, Meyer Vega LR, Edge SB,
Greene FL, Byrd DR, Brookland RK, Washington MK and Compton CC;
American Joint Committee on Cancer (AJCC), : AJCC cancer staging
manual. 8th edition. Springer; New York, NY, USA: pp. 10322017
|
|
19
|
Olsson E, Winter C, George A, Chen Y,
Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D and van Westen D:
Serial monitoring of circulating tumor DNA in patients with primary
breast cancer for detection of occult metastatic disease. EMBO Mol
Med. 7:1034–1047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vlataki K, Antonouli S, Kalyvioti C,
Lampri E, Kamina S, Mauri D, Harissis HV and Magklara A:
Circulating tumor DNA in the management of early-stage breast
cancer. Cells. 12:15732023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Magbanua MJM, Swigart LB, Wu HT, Hirst GL,
Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al:
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects
response and survival. Ann Oncol. 32:229–239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fiste O, Liontos M, Koutsoukos K, Terpos
E, Dimopoulos MA and Zagouri F: Circulating tumor DNA-based
predictive biomarkers in breast cancer clinical trials: A narrative
review. Ann Transl Med. 8:16032020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adejolu M, Huo L, Rohren E, Santiago L and
Yang WT: False-positive lesions mimicking breast cancer on FDG PET
and PET/CT. AJR Am J Roentgenol. 198:W304–W314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garcia-Murillas I, Schiavon G, Weigelt B,
Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa
I, et al: Mutation tracking in circulating tumor DNA predicts
relapse in early breast cancer. Sci Transl Med. 7:302ra1332015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lipsyc-Sharf M, de Bruin EC, Santos K,
McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM,
Partridge AH, et al: Circulating tumor DNA and late recurrence in
high-risk hormone receptor-positive, human epidermal growth factor
receptor 2-negative breast cancer. J Clin Oncol. 40:2408–2419.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Magbanua MJM, van't Veer L, Clark AS,
Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C,
et al: Outcomes and clinicopathologic characteristics associated
with disseminated tumor cells in bone marrow after neoadjuvant
chemotherapy in high-risk early stage breast cancer: The I-SPY
SURMOUNT study. Breast Cancer Res Treat. 198:383–390. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cavallone L, Aguilar-Mahecha A, Lafleur J,
Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E,
Majewski J, et al: Prognostic and predictive value of circulating
tumor DNA during neoadjuvant chemotherapy for triple negative
breast cancer. Sci Rep. 10:147042020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coombes RC, Page K, Salari R, Hastings RK,
Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, et al:
Personalized detection of circulating tumor DNA antedates breast
cancer metastatic recurrence. Clin Cancer Res. 25:4255–4263. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cailleux F, Agostinetto E, Lambertini M,
Rothé F, Wu HT, Balcioglu M, Kalashnikova E, Vincent D, Viglietti
G, Gombos A, et al: Circulating tumor DNA after neoadjuvant
chemotherapy in breast cancer is associated with disease relapse.
JCO Precis Oncol. 6:e22001482022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin PH, Wang MY, Lo C, Tsai LW, Yen TC,
Huang TY, Huang WC, Yang K, Chen CK, Fan SC, et al: Circulating
tumor DNA as a predictive marker of recurrence for patients with
stage II–III breast cancer treated with neoadjuvant therapy. Front
Oncol. 11:7367692021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee TH, Kim H, Kim YJ, Park WY, Park W,
Cho WK and Kim N: Implication of pre- and post-radiotherapy ctDNA
dynamics in patients with residual triple-negative breast cancer at
surgery after neoadjuvant chemotherapy: Findings from a prospective
observational study. Cancer Res Treat. Nov 10–2023.(Epub ahead of
print).
|
